60-minute Program
Description
Many of the patients with type 2 diabetes you see every week are also living with MASH, and for those with moderate to advanced liver fibrosis there is now an FDA approved treatment option. This webinar introduces diabetes care and education specialists and advanced practice practitioners (APPs) to Rezdiffra (resmetirom): who it is indicated for, how it works, and what the clinical data show.
Building on our earlier MASLD/MASH disease state programs with this audience, this session moves from recognition to action. You will learn which patients may be appropriate for treatment, what to expect when starting therapy, and how monitoring and follow up fit into the care you already provide.
Learning Objectives
After attending this webinar, participants will be able to:
1. State the FDA approved indication for Rezdiffra (resmetirom) and explain its mechanism of action.
2. Summarize key efficacy and safety data supporting Rezdiffra in appropriate patients with MASH and moderate to advanced fibrosis.
3. Apply practical considerations for patient selection, treatment initiation, and ongoing monitoring in patients with type 2 diabetes and MASH.
Sponsor
This webinar is sponsored by Madrigal Pharmaceuticals.
Disclaimer
This is a promotional, product focused educational program sponsored by Madrigal Pharmaceuticals. There is no CE/CME credit for this activity.
Agenda
Welcome and introductions (5 min)
Brief recap: MASH and fibrosis in the patient with type 2 diabetes (5 min)
Rezdiffra: indication, mechanism of action, and place in therapy (15 min)
Clinical trial data: efficacy and safety overview (15 min)
Practical considerations: patient selection, dosing, monitoring, and access support (10 min)
Q&A (10 min)
Access Period
You will have access to this webinar for a period of six months after you enroll, or until the activity's expiration date of 8/25/2028, whichever comes first.